市場調査レポート

商品コード

1532127

臨床試験イメージングの世界市場の評価：サービス別、モダリティ別、治療領域別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Clinical Trial Imaging Market Assessment, By Services, By Modality, By Therapeutic Area, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年08月13日
発行: Market Xcel - Markets and Data
ページ情報: 英文 245 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 648,270円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 821,142円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,181,292円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の臨床試験イメージングの市場規模は、2023年の13億5,000万米ドルから2031年に25億米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで8.01%の成長が見込まれます。市場は、研究開発費の増加、医用画像企業の拡大、臨床研究機関（CRO）の増加などの要因によって牽引されています。

医用画像は、先進のライフサイエンス機器やキットの開発に不可欠です。医用画像市場は常に変化しているにもかかわらず、バイオテクノロジー産業と製薬産業は一貫した成長を示しています。これは、医療機器の臨床試験を促進する革新的なイメージング技術の採用を含む、医用画像企業への投資の増加やM&Aによるところが大きいです。技術の進歩により、臨床試験の画像データの収集、解釈、提出が大幅に改善されています。技術に基づくイメージング、特に画像解析ソフトウェアは、統一性、データ品質、柔軟性、コンプライアンスなど、臨床研究に複数の利点をもたらします。例えば、画像解析ソフトウエアは、撮影時点を評価することにより、読影医の誘導や監督に使用することができます。さらに、処理能力の向上とともに画像技術の利用が増加しており、臨床試験におけるイメージングの利用が加速すると予測されます。Quantitative Imaging Biomarkers Alliance（QIBA）プログラムは、臨床試験において科学的かつ正確に定義された転帰を達成するために、標準化された手法とイメージングプロセスを開発しました。

2024年5月、Parexel International Corporation（Calyx Medical Imaging）は、既存のフロントライン治療に失敗した転移性メラノーマ患者に対する細胞治療であるIovance BiotherapeuticのAmtagvi（lifileucel）の極めて重要なフェーズII臨床試験への関与を発表しました。Calyxは、臨床試験の画像診断コンポーネントの開発と実施を支援しました。こうして、60の調査施設が画像評価手法に従って、患者のCT、磁気共鳴画像法（MRI）、陽電子放射断層撮影法（PET）、皮膚撮影写真を収集することができました。

研究開発費の増加

研究開発（R&D）費の増加は、臨床試験イメージング市場の成長の主な促進要因です。製薬企業やバイオテクノロジー企業は、新薬や新治療法を求めて研究開発への投資を拡大しており、効果的な臨床試験システムが必要とされています。これらの企業が研究開発により多くの資金を投じるにつれ、新薬の有効性と安全性を判断する上でイメージングが不可欠となるため、臨床試験イメージングサービスのニーズが高まっています。Qureight Ltd.は、臨床試験イメージングを通じて新薬開発のイメージングを促進するため、850万米ドルに相当するSeries Aラウンドの完了を発表しました。Qureight Ltd.のデジタルインフラハウスは、徹底的な検査に向けてさまざまな医療データを管理しています。Qureight Ltd.は、NHS Englandとのデータ契約を通じて独自の医療アクセスを有しており、CTスキャン、バイオマーカー、その他の臨床試験エンドポイントを病院や臨床研究機関（CRO）からリアルタイムで直接収集することができます。

医用画像企業の拡大が市場成長を促進

医用画像企業は、診断能力の向上と技術の進歩に対する需要の高まりにより成長を続けています。注目すべき発展として、さまざまなモダリティやイメージング位置でポイントオブケア診断を提供するポケットサイズの超音波機器など、ポータブルなハンドヘルドイメージング技術の製造があります。さらに、画像診断システムにAIや機械学習を組み込むことで、診断精度とワークフローの効率が向上します。Siemens HealthineersやGE Healthcareなどの企業は、ポータブルMRIシステムや自動X線スキャナーなどの画期的な技術を導入し、アクセシビリティの向上と業務の迅速化を図っています。2023年12月、GE Healthcare Technologies Inc.は、Radiological Society of America Scientific Sessions and Annual Meetings（RSNA 2023）で、AIベースの新しいMRIマシンの発売を発表しました。

当レポートでは、世界の臨床試験イメージング市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

市場規模の分析と予測
- 金額
市場シェア分析と予測
- サービス別
- モダリティ別
- 治療領域別
- エンドユーザー別
- 地域別
- 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
市場マップ分析（2023年）
- サービス別
- モダリティ別
- 治療領域別
- エンドユーザー別
- 地域別

第5章北米の臨床試験イメージング市場の見通し（2017年～2031年）

市場規模の分析と予測
- 金額
市場シェア分析と予測
- サービス別
- モダリティ別
- 治療領域別
- エンドユーザー別
- シェア：国別
市場の評価：国別
- 米国の臨床試験イメージング市場の見通し（2017年～2031年）
- カナダ
- メキシコ

第6章欧州の臨床試験イメージング市場の見通し（2017年～2031年）

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
ポーランド

第7章アジア太平洋の臨床試験イメージング市場の見通し（2017年～2031年）

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第8章南米の臨床試験イメージング市場の見通し（2017年～2031年）

ブラジル
アルゼンチン

第9章中東・アフリカの臨床試験イメージング市場の見通し（2017年～2031年）

サウジアラビア
アラブ首長国連邦
南アフリカ
イスラエル

第10章需給分析

第11章輸入と輸出の分析

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章 PESTLE分析

第15章価格分析

第16章市場力学

市場促進要因
市場の課題

第17章市場の動向と発展

第18章規制枠組みとイノベーション

臨床試験
規制当局の承認

第19章特許情勢

第20章ケーススタディ

第21章競合情勢

マーケットリーダー上位5社の競合マトリクス
上位5社のSWOT分析
主要企業上位10社の情勢
- Koninklijke Philips N.V.
- Navitas Clinical Research Inc.
- Parexel International Corporation
- Medpace Holdings Inc
- Radiant Sage LLC
- Clario Inc
- Icon Plc
- Ixico Plc
- ProScan Imaging LLC
- Resonance Health Ltd.

第22章戦略的推奨

第23章当社について、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 3. Global Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 4. Global Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 5. Global Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 6. Global Clinical Trial Imaging Market Share (%), By Region, 2017-2031F
Figure 7. North America Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 8. North America Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 9. North America Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 10. North America Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 11. North America Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 12. North America Clinical Trial Imaging Market Share (%), By Country, 2017-2031F
Figure 13. United States Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 14. United States Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 15. United States Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 16. United States Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 17. United States Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 18. Canada Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 19. Canada Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 20. Canada Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 21. Canada Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 22. Canada Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 23. Mexico Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 24. Mexico Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 25. Mexico Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 26. Mexico Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 27. Mexico Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 28. Europe Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 29. Europe Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 30. Europe Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 31. Europe Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 32. Europe Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 33. Europe Clinical Trial Imaging Market Share (%), By Country, 2017-2031F
Figure 34. Germany Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 35. Germany Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 36. Germany Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 37. Germany Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 38. Germany Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 39. France Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 40. France Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 41. France Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 42. France Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 43. France Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 44. Italy Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 45. Italy Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 46. Italy Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 47. Italy Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 48. Italy Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 49. United Kingdom Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 50. United Kingdom Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 51. United Kingdom Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 52. United Kingdom Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 53. United Kingdom Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 54. Russia Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 55. Russia Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 56. Russia Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 57. Russia Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 58. Russia Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 59. Netherlands Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 60. Netherlands Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 61. Netherlands Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 62. Netherlands Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 63. Netherlands Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 64. Spain Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 65. Spain Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 66. Spain Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 67. Spain Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 68. Spain Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 69. Turkey Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 70. Turkey Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 71. Turkey Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 72. Turkey Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 73. Turkey Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 74. Poland Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 75. Poland Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 76. Poland Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 77. Poland Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 78. Poland Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 79. South America Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 80. South America Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 81. South America Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 82. South America Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 83. South America Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 84. South America Clinical Trial Imaging Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 86. Brazil Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 87. Brazil Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 88. Brazil Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 89. Brazil Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 90. Argentina Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 91. Argentina Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 92. Argentina Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 93. Argentina Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 94. Argentina Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 95. Asia-Pacific Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 96. Asia-Pacific Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 97. Asia-Pacific Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 98. Asia-Pacific Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 99. Asia-Pacific Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 100. Asia-Pacific Clinical Trial Imaging Market Share (%), By Country, 2017-2031F
Figure 101. India Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 102. India Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 103. India Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 104. India Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 105. India Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 106. China Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 107. China Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 108. China Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 109. China Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 110. China Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 111. Japan Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 112. Japan Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 113. Japan Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 114. Japan Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 115. Japan Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 116. Australia Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 117. Australia Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 118. Australia Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 119. Australia Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 120. Australia Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 121. Vietnam Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 122. Vietnam Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 123. Vietnam Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 124. Vietnam Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 125. Vietnam Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 126. South Korea Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 127. South Korea Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 128. South Korea Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 129. South Korea Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 130. South Korea Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 131. Indonesia Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 132. Indonesia Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 133. Indonesia Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 134. Indonesia Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 135. Indonesia Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 136. Philippines Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 137. Philippines Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 138. Philippines Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 139. Philippines Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 140. Philippines Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 141. Middle East & Africa Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 142. Middle East & Africa Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 143. Middle East & Africa Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 144. Middle East & Africa Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 145. Middle East & Africa Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 146. Middle East & Africa Clinical Trial Imaging Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 148. Saudi Arabia Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 149. Saudi Arabia Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 150. Saudi Arabia Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 151. Saudi Arabia Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 152. UAE Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 153. UAE Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 154. UAE Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 155. UAE Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 156. UAE Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 157. South Africa Clinical Trial Imaging Market, By Value, In USD Billion, 2017-2031F
Figure 158. South Africa Clinical Trial Imaging Market Share (%), By Services, 2017-2031F
Figure 159. South Africa Clinical Trial Imaging Market Share (%), By Modality, 2017-2031F
Figure 160. South Africa Clinical Trial Imaging Market Share (%), By Therapeutic Area, 2017-2031F
Figure 161. South Africa Clinical Trial Imaging Market Share (%), By End-user, 2017-2031F
Figure 162. By Services Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By Therapeutic Area Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11742

Global clinical trial imaging market is projected to witness a CAGR of 8.01% during the forecast period 2024-2031, growing from USD 1.35 billion in 2023 to USD 2.50 billion in 2031. The global clinical trial imaging market is being driven by factors such as growing expenditures in research and development, expansion of medical imaging companies, and increasing number of Clinical Research Organizations (CROs).

Medical imaging is essential for the development of advanced life science devices and kits. Despite the ever-changing nature of the medical imaging market, the biotechnology and pharmaceutical industries are experiencing consistent growth. This is mostly owing to increased investment in medical imaging firms, and mergers and acquisitions including the adoption of innovative imaging technology to facilitate clinical trials for medical devices. Technological advancements are significantly improving the collection, interpretation, and submission of clinical trial imaging data. Technology-based imaging, particularly image analysis software, brings several advantages to clinical research, including uniformity, data quality, flexibility, and compliance. For instance, image analysis software may be used to guide and supervise a reader by evaluating imaging points in time. Furthermore, the increasing use of imaging technologies, along with improved processing power, is projected to accelerate the use of imaging in clinical trials. The Quantitative Imaging Biomarkers Alliance (QIBA) program has developed standardized methodologies and imaging processes to achieve scientifically and precisely defined outcomes in clinical studies.

In May 2024, Parexel International Corporation (Calyx Medical Imaging) announced its involvement in the pivotal phase II clinical study of Iovance Biotherapeutic's Amtagvi (lifileucel), a cell therapy for people with metastatic melanoma who have failed existing front-line treatments. Calyx helped develop and implement the imaging components of trials. Thus, 60 investigation sites were able to collect patient CT, magnetic resonance imaging (MRI), positron emission tomography (PET), and skin photography pictures in accordance with the image review methodology.

Growing Expenditures in Research and Development

Rising research and development (R&D) expenditures are a major driver for the growth of the clinical trial imaging market. Pharmaceutical and biotechnology businesses are growing their investment in R&D in search of new drugs and cures, necessitating effective clinical trial systems. As these corporations devote more money to R&D, the need for clinical trial imaging services increases, as imaging is critical in determining the efficacy and safety of new medicines. Qureight Ltd. announced their Series A round completion worth USD 8.5 million for expediting drug development imaging through clinical trial imaging. Qureight Ltd.'s digital infrastructure houses curates a variety of medical data for thorough examination. Qureight Ltd. has unique healthcare access through NHS England data contracts, allowing it to collect CT scans, biomarkers, and other trial endpoints directly from hospitals or clinical research organizations (CROs) in real time.

Expansion of Medical Imaging Companies to Drive Market Growth

Medical imaging firms are growing due to increased demand for enhanced diagnostic capabilities and technical advancements. Notable developments include manufacturing of portable and handheld imaging technologies, such as pocket-sized ultrasound devices, which provide point-of-care diagnostics in different modalities and imaging positions. Additionally, incorporating artificial intelligence (AI) and machine learning into imaging systems improves diagnosis accuracy and workflow efficiency. Companies such as Siemens Healthineers and GE Healthcare are introducing revolutionary technologies such as portable MRI systems and automated x-ray scanners to increase accessibility and accelerate operations. In December 2023, GE Healthcare Technologies Inc. announced the launch of its new AI-based MRI machine at the Radiological Society of America Scientific Sessions and Annual Meetings (RSNA 2023).

CT Scans Dominate the Global Clinical Trial Imaging Market Share

Computed tomography (CT) devices have been frequently used in clinical trial imaging due to their ability to produce detailed images of internal organs. CT scans use X-rays and computer processing to generate comprehensive cross-sectional digital images of the body, allowing clinicians and researchers to detect and quantify changes in tissues and organs over time. CT scans are secure and convenient for patients and researchers. Furthermore, researchers prefer CT scans as they can generate large volumes of data in a short period of time, which is useful for collecting and analyzing data from several patients to detect trends and patterns. The fast-track coronary artery bypass grafting (CABG) study, was led by the University's CORRIB research center for advanced imaging and core lab. Heart surgeons planned and performed CABG using non-invasive cardiac-CT scan images with the help of HeartFlow's AI-powered blood flow analysis, the doctors were able to identify problems in patient's coronary arteries.

Oncology to Account Dominant Market Share

Oncology is the leading segment amongst different types of therapeutic areas. The factors such as high prevalence of cancer cases and constant need for new and innovative therapies to treat various cancer types are expected to fuel market growth. Oncology trials often involve complex imaging requirements due to the need to assess tumor size, treatment responses, and disease progression. Various imaging modalities, such as CT scans, MRI, PET scans, and others, are used to evaluate the effectiveness of cancer treatments. This complexity results in a larger share of the market being dedicated to oncology.

Future Market Scenario (2024-2031F)

Future clinical trials will be increasingly employed with multi-modal imaging techniques, combining various imaging modalities such as MRI, CT, and PET. This approach will offer a comprehensive view of anatomical and physiological processes, facilitating better correlation of findings and improving the overall understanding of pathologies.

The use of wearable devices will provide continuous, real-time health data from trial participants. The technology aims to enhance patient engagement and reduce the burden of participation by allowing remote monitoring, thus making clinical trials more accessible and patient centric.

AI is set to revolutionize clinical trial imaging by enhancing diagnostic accuracy and efficiency. AI algorithms will improve image quality, reduce scan times, and automate tasks such as image interpretation and report generation. It will allow radiologists to focus on more complex cases while ensuring timely and precise disease detection.

The trend towards decentralized clinical trials will continue, leveraging technology to conduct trials remotely. It will involve partnerships with end-to-end solution providers who can manage imaging logistics, data harmonization, and secure analysis, ultimately enhancing trial efficiency and participant experience.

Key Players Landscape and Outlook

Several medical imaging companies and clinical research organizations are growing in the global clinical trial imaging market by planning and adopting new strategies. New agreements, contracts, mergers and acquisitions, investments, and partnerships, along with major strategic initiatives through which companies are increasing their market shares.

Pie Medical Imaging Inc., a global leader in cardiac imaging, announced in June 2024 its enrollment in FASTIII, a multi-center randomized clinical trial. The trial is investigating the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures. The vFFR can determine whether a coronary artery narrowing is functionally substantial and requires revascularization.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Clinical Trial Imaging Market Outlook, 2017-2031F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Services
  - 4.2.1.1. Clinical Trial Design and Consultation Services
  - 4.2.1.2. Reading and Analytical Services
  - 4.2.1.3. Operational Imaging Services
  - 4.2.1.4. System and Technology Support Services
  - 4.2.1.5. Project and Data Management
- 4.2.2. By Modality
  - 4.2.2.1. CT Scan
  - 4.2.2.2. MRI
  - 4.2.2.3. X-Ray
  - 4.2.2.4. Ultrasound
  - 4.2.2.5. PET Scan
  - 4.2.2.6. Echocardiogram (ECHO)
  - 4.2.2.7. Optical Coherence Tomography (OCT)
  - 4.2.2.8. Others
- 4.2.3. By Therapeutic Area
  - 4.2.3.1. Oncology
  - 4.2.3.2. Infectious Diseases
  - 4.2.3.3. Neurology
  - 4.2.3.4. Cardiovascular Diseases
  - 4.2.3.5. Endocrinology
  - 4.2.3.6. Others
- 4.2.4. By End-user
  - 4.2.4.1. Pharmaceutical and Biotechnology Companies
  - 4.2.4.2. Medical Device Manufacturers
  - 4.2.4.3. Contract Research Organizations
  - 4.2.4.4. Academic and Government Research Organizations
- 4.2.5. By Region
  - 4.2.5.1. North America
  - 4.2.5.2. Europe
  - 4.2.5.3. Asia-Pacific
  - 4.2.5.4. South America
  - 4.2.5.5. Middle East and Africa
- 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
- 4.3.1. By Services
- 4.3.2. By Modality
- 4.3.3. By Therapeutic Area
- 4.3.4. By End-user
- 4.3.5. By Region

5. North America Clinical Trial Imaging Market Outlook, 2017-2031F*

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Services
  - 5.2.1.1. Clinical Trial Design and Consultation Services
  - 5.2.1.2. Reading and Analytical Services
  - 5.2.1.3. Operational Imaging Services
  - 5.2.1.4. System and Technology Support Services
  - 5.2.1.5. Project and Data Management
- 5.2.2. By Modality
  - 5.2.2.1. CT Scan
  - 5.2.2.2. MRI
  - 5.2.2.3. X-Ray
  - 5.2.2.4. Ultrasound
  - 5.2.2.5. PET Scan
  - 5.2.2.6. Echocardiogram (ECHO)
  - 5.2.2.7. Optical Coherence Tomography (OCT)
  - 5.2.2.8. Others
- 5.2.3. By Therapeutic Area
  - 5.2.3.1. Oncology
  - 5.2.3.2. Infectious Diseases
  - 5.2.3.3. Neurology
  - 5.2.3.4. Cardiovascular Diseases
  - 5.2.3.5. Endocrinology
  - 5.2.3.6. Others
- 5.2.4. By End-user
  - 5.2.4.1. Pharmaceutical and Biotechnology Companies
  - 5.2.4.2. Medical Device Manufacturers
  - 5.2.4.3. Contract Research Organizations
  - 5.2.4.4. Academic and Government Research Institutes
- 5.2.5. By Country Share
  - 5.2.5.1. United States
  - 5.2.5.2. Canada
  - 5.2.5.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Clinical Trial Imaging Market Outlook, 2017-2031F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Services
      - 5.3.1.2.1.1. Clinical Trial Design and Consultation Services
      - 5.3.1.2.1.2. Reading and Analytical Services
      - 5.3.1.2.1.3. Operational Imaging Services
      - 5.3.1.2.1.4. System and Technology Support Services
      - 5.3.1.2.1.5. Project and Data Management
    - 5.3.1.2.2. By Modality
      - 5.3.1.2.2.1. CT Scan
      - 5.3.1.2.2.2. MRI
      - 5.3.1.2.2.3. X-Ray
      - 5.3.1.2.2.4. Ultrasound
      - 5.3.1.2.2.5. PET Scan
      - 5.3.1.2.2.6. Echocardiogram (ECHO)
      - 5.3.1.2.2.7. Optical Coherence Tomography (OCT)
      - 5.3.1.2.2.8. Others
    - 5.3.1.2.3. By Therapeutic Area
      - 5.3.1.2.3.1. Oncology
      - 5.3.1.2.3.2. Infectious Diseases
      - 5.3.1.2.3.3. Neurology
      - 5.3.1.2.3.4. Cardiovascular Diseases
      - 5.3.1.2.3.5. Endocrinology
      - 5.3.1.2.3.6. Others
    - 5.3.1.2.4. By End-user
      - 5.3.1.2.4.1. Pharmaceutical and Biotechnology Companies
      - 5.3.1.2.4.2. Medical Device Manufacturers
      - 5.3.1.2.4.3. Contract Research Organizations
      - 5.3.1.2.4.4. Academic and Government Research Institutes
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Clinical Trial Imaging Market Outlook, 2017-2031F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland

7. Asia-Pacific Clinical Trial Imaging Market Outlook, 2017-2031F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Clinical Trial Imaging Market Outlook, 2017-2031F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Clinical Trial Imaging Market Outlook, 2017-2031F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

16.1. Market Drivers
16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

18.1. Clinical Trials
18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

21.1. Competition Matrix of Top 5 Market Leaders
21.2. SWOT Analysis for Top 5 Players
21.3. Key Players Landscape for Top 10 Market Players
- 21.3.1. Koninklijke Philips N.V.
  - 21.3.1.1. Company Details
  - 21.3.1.2. Key Management Personnel
  - 21.3.1.3. Products and Services
  - 21.3.1.4. Financials (As Reported)
  - 21.3.1.5. Key Market Focus and Geographical Presence
  - 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 21.3.2. Navitas Clinical Research Inc.
- 21.3.3. Parexel International Corporation
- 21.3.4. Medpace Holdings Inc
- 21.3.5. Radiant Sage LLC
- 21.3.6. Clario Inc
- 21.3.7. Icon Plc
- 21.3.8. Ixico Plc
- 21.3.9. ProScan Imaging LLC
- 21.3.10. Resonance Health Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

臨床試験イメージングの世界市場の評価：サービス別、モダリティ別、治療領域別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Clinical Trial Imaging Market Assessment, By Services, By Modality, By Therapeutic Area, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の臨床試験イメージング市場の見通し（2017年～2031年）

第5章 北米の臨床試験イメージング市場の見通し（2017年～2031年）

第6章 欧州の臨床試験イメージング市場の見通し（2017年～2031年）

第7章 アジア太平洋の臨床試験イメージング市場の見通し（2017年～2031年）

第8章 南米の臨床試験イメージング市場の見通し（2017年～2031年）

第9章 中東・アフリカの臨床試験イメージング市場の見通し（2017年～2031年）

第10章 需給分析

第11章 輸入と輸出の分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析